- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03388099
Impact of Gonadotrophin REceptor Polimorphisms on the Relationship Between Serum AMH and Ovarian Response (GREPAMOR)
Study Overview
Status
Detailed Description
Serum AMH has shown to have a high predictive capability of the ovarian response to stimulation for IVF. On the other hand, patients who are carriers of polymorphisms in the FSH and LH receptors, have shown to need higher doses of gonadotrophins for ovarian stimulation. The proportion of carriers has been described to be around 20% of the population. Nevertheless, the determination of these polymorphisms is not performed in routine practice. It is unknown if their presence affects to the relationship between serum AMH levels and ovarian response.
This is a prospective, single center, non-interventional, cohorts study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46015
- Valencian Institute of Infertility, IVI RMA. Valencia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18-45 years of age presenting to IVF clinic
- BMI of 18-35 kg/m2
- Having been tested for serum AMH with the Elecsys assay
- Being planned to undergo ovarian stimulation cycle for IVF with the GnRH antagonist protocol
- Signed written informed consent or waiver
Exclusion Criteria:
- Current or past disease affecting ovaries, gonadotropin or sex steroid
- Current hormone therapy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
patients with FSH/LH polymorphisms
Infertile patients will undergo an ovarian stimulation with FSH and/or hMG.
Doses will be chosen according to BMI, Antral follicle count, AMH and age.
|
|
patients without FSH/LH polymorphisms
Infertile patients will undergo an ovarian stimulation with FSH and/or hMG.
Doses will be chosen according to BMI, Antral follicle count, AMH and age.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gonadotrophin receptor polymorphisms and ovarian response and AMH value
Time Frame: 1 year
|
To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
polymorphisms in the FSH receptor (FSHR) variant N680S
Time Frame: 1 year
|
To define the incidence of carriers of polymorphisms in the FSH receptor (FSHR) variant N680S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
|
1 year
|
|
polymorphisms in the LH receptor (LHR) variant N312S
Time Frame: 1 year
|
To define the incidence of carriers of polymorphisms in the LH receptor (LHR) variant N312S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
|
1 year
|
|
Doses of gonadotrophin needed and polymorphisms
Time Frame: 1 year
|
To analyse the doses of gonadotrophins needed for stimulation on each group of patients
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1706-VLC-058-EB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on antimüllerian Hormone and Gonadotrophin Receptor Polymorphism as Predictors of Ovarian Response
-
AGO Study GroupEssex Pharma GmbH; MedServ. GmbH, WiesbadenCompletedCervical Cancers | Cancer of the Ovary Treated as 2nd Line Therapy | Muellerian Mixed Tumours | Tumours of the Uterus | Non-Epithelial Ovarian TumoursGermany
-
Maaynei Hayesha Medical CenterUnknownPolycystic Ovary Syndrome | Hyperandrogenism | Single Nucleotide Polymorphism | AnovulationIsrael
-
Healing Hope InternationalEnrolling by invitationQuality of Life | Vasomotor Symptoms | Menopause | Cell Therapy | Hormone Disturbance | Premature Ovarian Failure | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men | Diminished Ovarian Reserve | Perimenopause | Vasomotor Symptoms Associated With Menopause | Premature Ovarian Failure... and other conditionsMexico
-
Incyclix BioRecruitingBreast Cancer | Ovarian Cancer | Solid Tumor | Metastatic Cancer | Advanced Cancer | Breast Cancer Metastatic | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | CCNE1 AmplificationUnited States, Australia
-
AbbVieActive, not recruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma | Platinum Resistant...United States, Australia, Israel, Japan, Puerto Rico, South Korea, Spain, Taiwan
-
NiKang Therapeutics, Inc.RecruitingSmall Cell Lung Carcinoma | Small Cell Lung Cancer | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid Tumor, Adult | Metastatic... and other conditionsUnited States
-
NiKang Therapeutics, Inc.TerminatedSmall Cell Lung Carcinoma | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid... and other conditionsUnited States
-
AmgenCompletedSolid TumorsUnited States, Belgium, Hungary, Canada, Denmark, Austria, Switzerland, Israel, United Kingdom, Czechia, France, Spain, Finland, Brazil, Australia, Japan, Italy, Netherlands, Poland, Greece, Argentina, Bulgaria, Romania, Portugal, Mexico, South Korea
-
Ikena OncologyGilead SciencesTerminatedRenal Cell Carcinoma | Breast Cancer | Gynecologic Cancer | Colorectal Cancer | Ovarian Cancer | Lung Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Hormone Receptor/Growth Factor Receptor-Negative Breast CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedAdult Solid Tumor | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Germ Cell Tumor | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative... and other conditionsUnited States